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Abstract
 
Somatic hypermutation specifically modifies rearranged immunoglobulin (Ig) genes in germinal
center (GC) B cells. However, the 
 
bcl-6
 
 gene can also acquire somatic mutations during the
GC reaction, indicating that certain non-Ig genes can be targeted by the somatic hypermuta-
tion machinery. The CD95 gene, implicated in negative selection of B lymphocytes in GCs, is
specifically expressed by GC B cells and was recently identified as a tumor suppressor gene be-
ing frequently mutated in (post) GC B cell lymphomas. In this study, the 5
 
9 
 
region (5
 
9
 
R) and/
or the last exon coding for the death domain (DD) of the CD95 gene were investigated in na-
ive, GC, and memory B cells from seven healthy donors. About 15% of GC and memory, but
not naive, B cells carried mutations within the 5
 
9
 
R (mutation frequency 2.5 
 
3
 
 10
 
2
 
4
 
 per base-
pair). Mutations within the DD were very rare but could be efficiently selected by inducing
CD95-mediated apoptosis: in 22 apoptosis-resistant cells, 12 DD mutations were found. These
results indicate that human B cells can acquire somatic mutations of the CD95 gene during the
GC reaction, which potentially confers apoptosis resistance and may counteract negative selec-
tion through the CD95 pathway.
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Introduction
 
Somatic hypermutation is a critical mechanism for the gen-
eration of diversity in the antibody repertoire (1). This pro-
cess takes place in antigen-experienced B cells within the
germinal center (GC), presumably the so-called centro-
blasts, and specifically targets rearranged Ig genes. The av-
erage mutation frequency of Ig V
 
H
 
 genes in normal human
centroblasts is 
 
z
 
6 
 
3
 
 10
 
2
 
2
 
 per basepair (2). Despite its high
specificity for rearranged Ig genes, the somatic hypermuta-
tion machinery was also shown to target the 
 
bcl-6
 
 gene in
normal GC B cells (3, 4). Accordingly, (post) GC B cell–
derived lymphomas also frequently harbor somatic 
 
bcl-6
 
mutations (4).
The CD95 (Apo-1/Fas) gene was recently proposed to
act as a tumor suppressor gene (5) and is, like 
 
bcl-6
 
, mutated
in a fraction of lymphomas derived from antigen-experi-
enced B cells. In the B lineage, CD95 is specifically ex-
pressed at the GC stage of differentiation (6, 7) and may
contribute to the propensity of GC B cells to apoptosis.
Occupancy of CD95 by CD95 ligand was therefore pro-
posed to represent an important mechanism for negative
selection of (e.g., autoreactive) B cells within the GC (7–
11). Although autoreactive B cells can bypass negative se-
lection in CD95-deficient 
 
lpr
 
 mice (12), affinity maturation
on the basis of positive selection by antigen appeared to re-
main undisturbed (6). 
 
lpr
 
 mice develop lymphadenopathy
and enlargement of liver and spleen and are prone to au-
toimmunity (12) and B cell lymphoma (13). Germline mu-
tations of the CD95 gene leading to autoimmune lym-
phoproliferative syndrome (ALPS) and predisposing to B
cell lymphoma and other malignancies have been observed
in humans as well (5, 14). Notably, the majority of these
patients develop follicular hyperplasia and progressive trans-
formation of GCs, leading to profound alterations of the
normal GC architecture (15).
Somatic mutations impairing the transduction of the ap-
optosis signal were observed in a number of lymphoid ma-
lignancies (16, 17). Deleterious mutations of exon IX of
the CD95 gene coding for the death domain (DD) act in a
dominant-negative way, which is likely due to the trimer-
ization of CD95 on the cell surface (14). The DD is a
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highly conserved region that is required and sufficient for
the transduction of the death signal (14).
During tumor progression, malignant cells frequently
lose their susceptibility to CD95-mediated apoptosis and
thus escape immunosurveillance and rejection (e.g., by
CD95 ligand expressing cytotoxic T cells; for review see
reference 18). In consequence, loss of CD95 function due
to somatic mutations should favor immune evasion of ma-
lignant cells.
In lymphomas derived from antigen-experienced B cells,
mutations of the CD95 gene may reflect increased mutabil-
ity due to the malignant transformation and defective DNA
repair pathways in the neoplastic cells. On the other hand,
such mutations may have been acquired by the precursor
cell of the tumor clone during the GC reaction. To test the
latter possibility, naive, GC, and memory B cells of healthy
donors were purified and analyzed for mutations of the
CD95 gene.
 
Materials and Methods
 
Cell Separation and Flow Cytometry.
 
For single-cell analysis, B
cell subsets were purified from reactive tonsils of seven donors
(aged from 3 to 41 y). CD38
 
1
 
CD77
 
1
 
 GC B cells were isolated as
previously described (19). Repeating the MACS™ enrichment of
CD77
 
1
 
 cells once, a purity of 
 
.
 
90% CD38
 
1
 
CD77
 
1
 
 cells was
obtained. From six donors, single CD38
 
1
 
CD77
 
1
 
 cells were
sorted directly into PCR tubes containing 20 
 
m
 
l of 1
 
3
 
 Expand
High Fidelity PCR buffer (Boehringer Mannheim) on a FACS
 
®
 
440 (Becton Dickinson). Tonsillar naive and memory B cells
were isolated from the flowthrough fraction (CD77
 
2
 
 cells). The
fraction of naive B cells was twice depleted from CD27-express-
ing cells, whereas the memory B cell fraction was twice enriched
for CD27 expression by MACS™. Naive B cells (IgD
 
1
 
IgM
 
1
 
CD20
 
1
 
CD27
 
2
 
) and memory B cells (IgD
 
2
 
IgM
 
2
 
Ig
 
k
 
1
 
CD27
 
1
 
) were then directly sorted into PCR tubes.
 
Cloning Procedure.
 
For an initial experiment, genomic DNA
was extracted from naive (IgD
 
1
 
CD27
 
2
 
) and GC (CD38
 
1
 
CD77
 
1
 
) B cells purified from tonsillar tissue of another donor
(20) and used for amplification of exon IX of the CD95 gene us-
ing Pfu Turbo polymerase (Stratagene) in 35 PCR cycles and
cloned into the pGEM-T cloning vector.
 
Single-Cell PCR.
 
For all sorted cells, a whole genome pream-
plification step (21) was performed. Aliquots of 4 
 
m
 
l from these
reactions were then subjected to two rounds of seminested PCR
amplification as previously described. In brief, rearranged V
 
H
 
genes were amplified using family-specific framework region I V
gene primers and two sets of J
 
H
 
 primers in a seminested approach
(19).
As depicted in Fig. 1, two regions of the CD95 gene were an-
alyzed by single-cell PCR. Exon IX coding for the DD was am-
plified using 5
 
9
 
-CAC TAA TGG GAA TTT CAT TTA GA-3
 
9
 
as external forward, 5
 
9
 
-TGG GAA TTT CAT TTA GAA AAA
CA-3
 
9
 
 as internal forward, 5
 
9
 
-TAA TTG CAT ATA CTC AGA
ACT GA-3
 
9
 
 as external reverse, and 5
 
9
 
-TAC TCA GAA CTG
AAT TTG TTG T-3
 
9
 
 as internal reverse primers in a nested
PCR (two amplification rounds of 35 and 45 cycles at an anneal-
ing temperature of 55
 
8
 
C). A 750-bp fragment encompassing the
5
 
9
 
 region of the CD95 gene (Fig. 1) was amplified using 5
 
9
 
-ACC
ACC GGG GCT TTT CGT GA-3
 
9
 
 as external forward, 5
 
9
 
-
TGA GCT CGT CTC TGA TCT CG-3
 
9
 
 as internal forward,
 
5
 
9
 
-TAT CTG TTC TGA AGG CTG CAG-3
 
9
 
 as external re-
verse, and 5
 
9
 
-CGG AGC GGA CCT TTG GCT-3
 
9
 
 as internal
reverse primers in a nested PCR at an annealing temperature of
58
 
8
 
C. Sequence analysis for cases II and III revealed that the so-
matic mutations within the 5
 
9
 
 region of the CD95 gene clustered
to a genomic region flanking the first exon. Thus, further analysis
focused on a 510-bp region using 5
 
9
 
-CTT CGC ATC AAG
GCC CAA GAA-3
 
9
 
 and 5
 
9
 
-AAG GCC CAA GAA AAG CAA
GTC-3
 
9
 
 as external and internal reverse primers, respectively.
PCR products were gel purified and directly sequenced using the
BigDye Terminator cycle sequencing kit and an automated se-
quencer (ABI 377; Applied Biosystems). To rule out Taq DNA
polymerase errors during the first and second rounds of PCR, 10
CD95 mutations were reproduced by amplification of the respec-
tive PCR products from two independent aliquots of the whole
genome preamplification reactions.
 
Selection of GC B Cells Carrying a Mutated CD95 DD.
 
After
MACS™ purification, the CD38
 
1
 
CD77
 
1
 
 GC B cells from do-
nors II–V were suspended in undiluted supernatants conditioned
by the lymphoblastoid marmoset cell line B95.8 that releases EBV
into the culture fluid. The GC B cells were cultured overnight at
37
 
8
 
C (humidified 5% CO
 
2
 
 atmosphere) in the presence of EBV
(22) and then transferred into multiple wells of a microtiter plate
at a density of 10
 
5
 
 cells per well. In accordance with previous
findings (22), we showed in an independent experiment that the
number of viable cells remained unchanged in these cultures,
whereas virtually all GC B cells died in the absence of EBV.
Thus, in the presence of EBV, the surviving B cells were rescued
from apoptosis presumably by EBV-dependent antiapoptotic sig-
nals. The EBV-containing culture medium was supplemented
with an agonistic antibody to CD95 (Beckman Coulter) at a con-
centration of 100 ng/ml. After 16 h of incubation, 
 
.
 
90% of the
GC B cells became apoptotic in the presence yet not in the ab-
sence of the agonistic anti-CD95 antibody, as assessed by mem-
brane staining for annexin V (CLONTECH Laboratories, Inc.;
see Fig. 2). In line with earlier findings (23), EBV confers pro-
longed survival to in vitro–cultured B cells but does not affect
sensitivity to CD95-mediated apoptosis. Single, nonapoptotic
GC B cells (annexin V–negative, propidium iodide–negative,
CD38
 
1
 
) were directly sorted into PCR tubes.
 
Statistics.
 
The levels of statistical significance were calculated
using the 
 
x
 
2
 
 test for rows and columns of contingency tables.
 
 P 
 
,
 
0.05 was considered statistically significant.
 
Results
 
To investigate whether normal B cells can acquire so-
matic mutations of the CD95 gene during the GC reac-
tion, in an initial experiment, exon IX of the CD95 gene
was amplified, cloned, and sequenced from genomic DNA
of naive and GC B cells (CD38
 
1
 
CD77
 
1
 
 centroblasts). In
21 clones from naive B cells, 1 mutation was found,
whereas in 30 clones from GC B cells, 4 clones were
mutated (Table I). This prompted us to investigate
CD95  mutations in single naive (IgD
 
1
 
IgM
 
1
 
CD27
 
2
 
), GC
(CD38
 
1
 
CD77
 
1
 
 centroblasts), and memory (IgD
 
2
 
IgM
 
2
 
Ig
 
k
 
1
 
CD27
 
1
 
) B cells from six further donors. The single-
cell approach was chosen because direct sequencing of
PCR products from single cells circumvents DNA poly-
merase–introduced mutations, which might pose a problem
in a low-level mutation analysis when PCR products are 
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cloned before sequencing. For each B cell subset, single
cells were isolated by fluorescence-activated cell sorting
from reactive tonsils of six donors (aged 3–41 y). From
these cells, a 750-bp fragment of the CD95 gene encom-
passing 5
 
9
 
 untranslated and coding regions of exon I and a
p53 responsive enhancer within the first intron was ana-
lyzed. This region (here collectively termed 5
 
9
 
 region
[5
 
9
 
R]; Fig. 1) is located 
 
z
 
100 bp downstream of the tran-
scription initiation site and was selected in analogy to the
 
bcl-6
 
 gene that was previously shown to harbor a major
cluster of somatic mutations within its 5
 
9
 
 regulatory regions
(4). In addition, a 440-bp fragment comprising exon IX
coding for the DD of CD95 was analyzed (Fig. 1). The pu-
rity of the sorted B cell subsets was verified by amplification
and sequencing of Ig V
 
H
 
 gene rearrangements from 8 naive
B cells (none mutated), 21 GC B cells (all mutated), and 16
memory B cells (all mutated; Table I).
Analyzing 5
 
9
 
R sequences from 135 B cells from 4 do-
nors, we detected two novel germline polymorphisms at
nucleotide positions 
 
1
 
275 and 
 
1
 
337 in two donors. For
the calculation of the mutation frequency, we took advan-
tage of these novel polymorphisms, as they allowed us to
 
Table I.
 
Somatic Mutations of the CD95 Gene in Naive, GC, and Memory B Cells
 
Mutated cells
 
*
 
B cell subset;
Phenotype Donor Method Overall 5
 
9R Exon IX Ig VH
Naive; I Cloning 1/21 ND 1/21 0/17‡
IgD1IgM1CD272 II Single cell 0/19 0/19 0/14 0/4
III Single cell 0/12 0/9 0/9 ND
IV Single cell 1/11 1/8 0/7 0/1
V Single cell 0/14 0/12 0/8 0/3
VI Single cell 0/14 ND 0/14 ND
VII Single cell 0/14 ND 0/14 ND
SII–VII Single cell 1/84¶ 1/48¶ 0/66¶ 0/8
GC; I Cloning 4/30 ND 4/30§ 13/13‡
CD381CD771 II Single cell 4/25 3/25 1/9§ 5/5
III Single cell 3/15 3/14 0/5 4/4
IV Single cell 2/15 1/10 1/6§ 4/4
V Single cell 3/14 3/11 0/2 4/4
VI Single cell 0/12 ND 0/12 ND
VII Single cell 0/11 ND 0/11 ND
SII–VII Single cell 12/92i¶ 10/60i 2/45¶ 17/17
Anti-CD95–resistant GC; II Single cell 5/5 3/4 3/5 ND
Annexin V–negative, III Single cell 1/7 0/2 1/7 2/2
CD381 IV Single cell 2/5 0/4 2/5 ND
V Single cell 1/5 ND 1/5 2/2
SII–V Single cell 9/22i 3/10i 7/22i 4/4
Memory; II Single cell 1/13 1/7 0/9 4/4
IgD2CD201CD271 III Single cell 2/8 2/4 0/8 5/5
IV Single cell 0/8 0/3 0/8 4/4
V Single cell 2/8 2/3 0/8 3/3
SII–V Single cell 5/37i 5/17i 0/33¶ 16/16
*Clones for donor I.
‡Genomic DNAs used in the cloning experiment were already studied in Jungnickel et al. (20).
§All cells/clones harbor replacement or truncating mutations.
iP , 0.05 as compared to naive B cells.
¶P , 0.05 as compared to anti-CD95–resistant GC B cells.1836 Somatic Mutation of the CD95 Gene in Germinal Center B Cells
distinguish between amplification of only one (40% of all
cells) or both alleles (60% of all cells) from a single cell (i.e.,
on average 1.6 alleles were amplified).
Notably, somatic mutations of the 59R of the CD95
gene were detected in z15% of GC and memory B cells
(Table I). Assuming that also in the noninformative cases on
average 1.6 alleles of the CD95 gene were amplified from
each cell, an overall mutation frequency of the 59R in GC
and memory B cells of 2.6 3 1024 per basepair can be cal-
culated. In contrast, in a total of 48 naive B cells, only one
mutation within the 59R was detected (Table I). As none of
the 22 mutations within the 59R (Table II) targeted the first
exon or the p53-responsive enhancer (Fig. 1), their func-
tional relevance remains unclear. Mutations within the DD
were very rare and only found in GC B cells (mutation fre-
quency in GC B cells 7 3 1025 per basepair).
To confirm that GC B cells harboring a mutated DD in-
deed occur within the GC (although at a low frequency)
Figure 1. Organization of the CD95 gene and distri-
bution of somatic mutations. The organization of the
CD95 gene (comprising exons I–IX) is depicted. From
single naive (IgD1IgM1CD272), GC (CD381CD771),
anti-CD95–resistant GC (annexin V–negative,
CD381), and memory (IgD2CD201CD271) B cells of
four donors, a 750-bp fragment encompassing 59 un-
translated (gray boxes) and coding (black boxes) regions
of the first exon and a p53-responsive intronic en-
hancer was amplified. From the same cells, a 440-bp
fragment containing exon IX coding for the DD of
CD95 was amplified. Two novel germline polymor-
phisms are indicated by vertical lines. Below, the distri-
bution of somatic mutations within the two regions of
GC and memory B cells is depicted (point mutations as
vertical lines and deletions as brackets).
Table II. Frequency of CD95 Mutations in Human B Cell Subsets; Single-Cell Analysis from Donors II–VII
Mutations per cell Mutation frequency
B cell subset; phenotype 59 region Exon IX 59 region Exon IX
3 1024/bp*
Naive; IgD1IgM1CD272 1/48 0/66‡ 0.3 ,0.2‡
GC; CD381CD771 12/60 2/45 2.5 0.7
anti-CD95–resistant GC; annexin V–negative, CD381 4/10 12/22 5.0 7.7
Memory; IgD2CD201CD271 6/17 0/33‡ 3.1 ,0.4‡
*Calculation of mutation frequencies is based on average amplification of 1.6 alleles from one cell. Mono- and biallelic amplification was distin-
guished by germline polymorphisms for the 59R and by mutations for the DD, respectively.
‡For calculation of mutation frequencies, 0 mutations was set to ,1 mutations in 33 and 66 cells.1837 Müschen et al. Brief Definitive Report
and to determine whether mutations of the DD have im-
pact on CD95-dependent apoptosis, an in vitro selection
experiment was performed (Fig. 2). As GC B cells undergo
apoptosis within a few hours under standard cell culture
conditions, they were rescued by short-term EBV infection
that does not yet lead to lymphoblastoid transformation
(22). Confirming previously published data (22), .80% of
the GC B cells were still viable after overnight culture. As
in vitro–cultured B cells retain their full sensitivity to
CD95-mediated apoptosis even after EBV immortalization
(23), an agonistic (apoptosis-inducing) antibody to CD95
was added to the GC B cells. After 16 h, .90% of the GC
B cells became apoptotic (annexin V–positive) in the pres-
ence yet not in the absence of the antibody (Fig. 2). Single
annexin V–negative, CD381 GC B cells were sorted and
analyzed for somatic mutations within the 59R and the
DD. In 22 cells, 12 DD mutations were found (7 mutated
cells, mutation frequency 7.7 3 1024 per basepair; Table
II). Compared with nonselected GC B cells, the frequency
of GC B cells harboring a mutant DD was significantly in-
creased within the anti-CD95–resistant population (P ,
0.01). Unexpectedly, the frequency of 59R mutations was
slightly increased compared with unselected GC B cells
(Table II). Among the 14 DD mutations detected in GC B
cells, two mutations creating a preterminal translation stop,
two deletions resulting in frameshift, and nine replacement
mutations were found. One silent mutation was detected in
a GC B cell that also harbored a replacement mutation.
Thus, it is indeed possible to selectively enrich GC B cells
carrying a mutated DD in vitro, indicating that the DD
mutations in GC B cells confer resistance to (or at least de-
lay of) CD95-mediated apoptosis.
Discussion
This study shows that normal human B cells can acquire
somatic mutations of the CD95 gene during the GC reac-
tion. CD95 is, like the bcl-6 gene, specifically expressed at
the GC stage of B cell differentiation and frequently mu-
tated in (post) GC B cell lymphomas. In comparison to
bcl-6, however, the frequency of somatic mutations within
the CD95 gene in (post) GC B cells is considerably lower
(3, 4). For both genes, it is conceivable that the mutations
are introduced as byproducts of somatic hypermutation act-
ing outside the Ig loci. It will be interesting to determine
whether this phenomenon is specific for a distinct subset of
GC-related genes or can affect any gene expressed con-
comitantly with the process of somatic hypermutation.
Somatic mutations in rearranged Ig genes and in the bcl-6
gene are largely confined to a genomic region of z1.5 kb
downstream of the transcription initiation site. This is com-
patible with the clustering of CD95 mutations within the
59R (as opposed to mutations within the DD, i.e., .15 kb
downstream of the transcription initiation site). As de-
scribed for both Ig and bcl-6 genes, a bias for transitions
over transversions (26:8) was observed for mutations in the
CD95 gene. While somatic mutations are preferentially in-
troduced at RGYW motifs in Ig and bcl-6 genes (4), this
was not evident for the 59 region of the CD95 gene. How-
ever, as not all RGYW motifs in Ig genes are mutational
hot spots, this does not argue against an involvement of the
hypermutation machinery (for review see reference 2).
From the finding that somatic mutations in the CD95
gene also occur in T cell–derived malignancies and solid
tumors (for review see reference 5), it is obvious that other
mechanisms can contribute to CD95 mutations. In line
with this view, the pattern of CD95 mutations in T cell
malignancies (i.e., large deletions rather than point muta-
tions) clearly differs from that described here. As neither T
cell neoplasms nor solid tumors have been analyzed for
mutations within the 59R of the CD95 gene so far, we
have amplified and sequenced this region from 48 mostly
high grade breast cancer samples and found no mutation
(Müschen, M., and D. Re, unpublished observation).
A fraction of somatic CD95 mutations, in particular
those within the DD, may indeed have significant impact
on the fate of a B cell within the GC. Truncating muta-
tions and also many replacement mutations within the DD
have been shown to act in a dominant negative manner
and are related to a clinical phenotype (ALPS; for review
Figure 2. In vitro selection of anti-CD95–resistant GC B cells. Tonsil-
lar mononuclear cells were stained for the GC markers CD38 and CD77
with  ,5% double-positive cells (A). After MACS™ enrichment for
CD771 cells, the purity of CD381CD771 B cells increases up to .90%.
From the gated population, single cells were sorted into PCR tubes for
further analysis (B). The purified CD381CD771 GC B cells were incu-
bated with EBV-containing supernatants and cultured overnight. There-
after, the GC B cells were incubated for 16 h in the absence (C) or pres-
ence (D) of an agonistic anti-CD95 antibody at 100 ng/ml. In .90% of
the GC B cells, the agonistic anti-CD95 antibody induced apoptosis (pos-
itive staining for annexin V; D). From the annexin V–negative, CD381
GC B cells (D, gate) that had not undergone apoptosis, single cells were
sorted into PCR tubes.1838 Somatic Mutation of the CD95 Gene in Germinal Center B Cells
see reference 5). Using an in vitro selection procedure, this
study provides direct evidence for the link between muta-
tions within the DD and resistance to CD95-mediated ap-
optosis: triggering CD95-mediated apoptosis in vitro re-
sulted in a 10-fold higher frequency of DD mutations in
the surviving cells (P , 0.01). That B cells harboring an in-
activated CD95 gene are indeed also positively selected
within the GC is supported by the finding that all mutated
DD sequences from GC B cells carried either replacement
or truncating mutations (Table I). The observation that
mutations within the 59R were apparently coselected with
DD mutations (Table II) might indicate that the mutations
within both regions were generated through the same
mechanism, namely somatic hypermutation as it is usually
targeted to rearranged Ig genes.
Several lines of evidence suggest that CD95 is important
for affinity maturation of B cells during the GC reaction:
survival signals through B cell receptor engagement and
costimulatory CD40 signaling confer resistance to CD95-
mediated apoptosis (9, 10, 24) and represent a means of
positive selection by antigen (1, 11). Hence, CD95 defi-
ciency in GC B cells due to somatic mutation might allow
GC B cells expressing mutant antibodies to bypass the
stringent selection mechanisms involved in affinity matura-
tion. While an earlier study of affinity maturation of the
antibody response to 4-hydroxy-3-nitrophenyl (NP) in lpr
mice did not support this possibility (6), recent data of
Takemori and colleagues, obtained in the same experimen-
tal system, indicate that CD95 indeed plays a role in GC B
cell selection (Takemori, T., personal communication).
The process of somatic hypermutation is a potential
source of self-reactive antibody specificities (1). Therefore,
autoreactive B cells are vigorously counterselected within
the GC (25). In CD95-deficient lpr mice (12) and humans
suffering from ALPS (14), autoreactive B cells producing
high levels of autoantibodies accumulate, indicating that
negative selection against autoreactivity is impaired (12). In
this study, GC B cells that had lost their sensitivity to
CD95-mediated apoptosis were detected in five donors at
young age (3 to 6 y). Although such mutations were only
found at a very low frequency, we can envision that these
cells may accumulate during the aging process and repre-
sent a potential source for autoantibody production.
Somatic mutations of the CD95 gene were previously
found in a number of (post) GC B cell lymphomas includ-
ing follicular lymphoma, diffuse large B cell lymphoma,
anaplastic large cell lymphoma (17), plasmocytoma (16),
and Hodgkin’s disease (26). The overall frequency of (post)
GC B cell lymphomas harboring one or more CD95 muta-
tions is z16% (for review see reference 5). Given that germ-
line mutations of the CD95 gene are related to lymphopro-
liferation and B cell lymphoma in humans and mice (13), it
was proposed that CD95 acts as a tumor suppressor gene
(5). As this study describes that normal GC B cells can also
acquire somatic mutations of the CD95 gene, it is unlikely
that these mutations already commit a GC B cell to malig-
nant transformation. Under the assumption of a multistep
lymphomagenesis, however, deleterious mutations within
the DD can favor the persistence of mutant GC B cells un-
til further transforming events take place.
A number of features of GC B cell physiology (e.g., high
proliferation rate, somatic hypermutation, class switch re-
combination) bear an inherent risk of malignant transfor-
mation (27). The finding of deleterious CD95 mutations in
GC B cells supports the concept that the GC reaction, be-
sides its physiological role, is a potential source of onco-
genic alterations predisposing to B cell lymphoma.
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